The medical landscape for diabetes is shifting, and transdermal GLP-1 delivery systems represent a exciting development. Unlike subcutaneous injections, this approach offers a less invasive way to deliver GLP-1 drugs. These transdermal systems steadily release the drug through the skin offering a stable dose of the beneficial agent, which can optim